SignPath Pharma (United States)
A clinical stage company with a unique drug development platform which creates heart-safe drugs.
Last updated September 1, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Signpath Pharma is a clinical stage company that has developed a platform technology (the CorreQT platform) which mitigates the cardiac side effects of other drugs, including cardiac arrhythmia and cardiac damage associated with chemotherapy. Its first clinical application is LipoCurc™, a proprietary liposomal formulation of curcumin administered intravenously, which has completed Phase 1a and 1b clinical trials in 70 human subjects. A Phase 2 trial in first line treatment of glioblastoma is underway.
History
Signpath Pharma is a clinical stage company. It has developed the CorreQT platform technology to mitigate cardiac side effects of other drugs. Its first clinical application is LipoCurc™, a proprietary liposomal formulation of curcumin administered intravenously. LipoCurc™ has completed Phase 1a and 1b clinical trials in 70 human subjects. A Phase 2 trial in first line treatment of glioblastoma is underway.
Products and positioning
LipoCurc™
A proprietary liposomal formulation of curcumin administered intravenously, with active and sustained levels of curcumin over 1000 times greater than traditional oral curcumin dosing, without cardiotoxicity.
CorreQT platform
A platform technology that mitigates the cardiac side effects of other drugs, including cardiac arrhythmia and cardiac damage associated with chemotherapy.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/signpath-pharma-united-states · Editorial policy · How profiles are compiled